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ARTICLE
Microenvironmental IL1β promotes breast cancer
metastatic colonisation in the bone via activation of
Wnt signalling
Rachel Eyre1, Denis G. Alférez 1, Angélica Santiago-Gómez 1, Kath Spence1, James C. McConnell2,
Claire Hart 3, Bruno M. Simões 1, Diane Lefley4, Claudia Tulotta4, Joanna Storer 1, Austin Gurney5,
Noel Clarke6, Mick Brown 3, Sacha J. Howell 1,7, Andrew H. Sims 8, Gillian Farnie9,
Penelope D. Ottewell 4* & Robert B. Clarke 1*
Dissemination of tumour cells to the bone marrow is an early event in breast cancer, however
cells may lie dormant for many years before bone metastases develop. Treatment for bone
metastases is not curative, therefore new adjuvant therapies which prevent the colonisation
of disseminated cells into metastatic lesions are required. There is evidence that cancer stem
cells (CSCs) within breast tumours are capable of metastasis, but the mechanism by which
these colonise bone is unknown. Here, we establish that bone marrow-derived IL1β stimulates
breast cancer cell colonisation in the bone by inducing intracellular NFkB and CREB signalling
in breast cancer cells, leading to autocrine Wnt signalling and CSC colony formation.
Importantly, we show that inhibition of this pathway prevents both CSC colony formation in
the bone environment, and bone metastasis. These findings establish that targeting IL1β-
NFKB/CREB-Wnt signalling should be considered for adjuvant therapy to prevent breast
cancer bone metastasis.
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Approximately half a million women die from breast cancerglobally each year1. These deaths are predominantly dueto metastatic disease, therefore developing new strategies
to prevent or treat metastasis are essential to reduce breast cancer
mortality. It is known that systemic spread is an early event in
breast cancer2,3, with disseminated tumour cells (DTCs) detect-
able in bone marrow at the time of primary tumour diagnosis4.
Based on this, targeting the early steps of metastasis is unlikely to
be an effective clinical strategy. However, in many cases DTCs lie
dormant in the bone marrow for long periods prior to overt
colonisation5,6, and preventing this colonisation provides a logical
treatment strategy to prevent the development of overt metas-
tases, and thus reduce mortality.
There is evidence that only a small subset of cancer stem cells
(CSCs) with an aggressive phenotype are capable of undergoing
metastasis7,8. Little is known, however, about the microenviron-
mental factors aiding the colonisation of disseminated CSCs
following their arrival in the bone marrow. In this work, we have
utilised in vitro culture of both primary human bone and primary
human breast cancer samples, along with in vivo bone metastasis
models, to identify specific bone marrow-derived factors and
subsequent downstream signalling in cancer cells stimulating
CSC colonisation in bone.
The inflammatory cytokine IL1β has long been proposed as an
important cytokine for metastasis, with recombinant IL1β first
shown to promote lung metastasis in mice over 25 years ago9.
More recently, in mouse models, IL1β has been shown to pro-
mote lung metastasis10, and inhibition of IL1β prevent bone
metastasis11,12. Clinically, it was observed in an atherosclerosis
study that patients taking the IL1β inhibitor Canakinumab
experienced reduced lung cancer incidence and mortality com-
pared to patients taking placebo13. However the mechanism
underpinning IL1β’s contribution to metastatic growth has not
yet been defined, limiting the use of inhibitors for anti-metastasis
therapy. Here, we demonstrate that in the bone metastatic niche,
microenvironmental IL1β promotes the ability of breast CSCs to
form colonies through activation of NFKB and CREB signalling,
Wnt ligand secretion and autocrine Wnt signalling in breast
cancer cells. Crucially, inhibition of this pathway prevents both
metastasis of breast cancer cells to bone in vivo, and CSC colony
formation in the bone environment in vitro.
We propose that inhibiting IL1β-NFKB/CREB-Wnt signalling
could be an important adjuvant therapeutic strategy in breast
cancer to prevent overt bone metastases forming from dis-
seminated tumour cells. Rapid translation of this approach would
be possible as inhibitors to this pathway are already either
licensed for other applications (Anakinra, Canakinumab, Sulfa-
salazine), or in clinical trials for cancer (Vantictumab, LGK974).
Results
Bone marrow-derived factors promote CSC colony formation.
To investigate the effect of bone marrow-derived factors on breast
CSC colony formation, bone marrow stroma from non-cancer
patients was grown in culture. Bone marrow cultures were grown
in continuous culture for 17 weeks (See Supplementary Fig. 1A
for annotated images of bone marrow growth, showing changes
in the cellular composition over time), with conditioned media
removed weekly. MCF-7 breast cancer cells were treated with
conditioned media from different weeks of bone marrow culture
(from week 3 onwards), and CSC colony formation assessed by
mammosphere formation14,15 (See Supplementary Fig. 1B for
bone marrow sample workflow). Conditioned media from bone
marrow which had been cultured for 3 weeks did not stimulate
CSC colony formation compared to treatment with control media
(media not conditioned by the bone marrow), whereas
conditioned media from bone marrow cultured for 5–17 weeks
(termed CM) significantly increased CSC colony formation
(Supplementary Fig. 1C). CM stimulated CSC colony formation
in 5/6 breast cancer cell lines (oestrogen receptor positive (ER+):
MCF-7 (p < 0.0001), T47D (p < 0.0001). oestrogen receptor
negative (ER−): SUM149 (p < 0.0001), SUM159 (p < 0.0001),
MDAMB231_BH (p < 0.0001)) (mammosphere formation and
representative mammosphere images shown in Fig. 1a). Inter-
estingly, CM did not stimulate mammosphere formation in
parental MDA-MB-231 cells, but was stimulatory in a bone
homing variant of this cell line (termed MDA-MB-231_BH)
(MDA-MB-231_IV derived in ref. 16). To determine if stimula-
tion of CSC colony forming activity was specific to bone marrow
stroma or could be generated by other bone cells, conditioned
media from the osteoblast cell line hFOB1.19 was also assessed
(oCM). This did not increase CSC colony formation compared to
control treatment in MCF-7 cells (Supplementary Fig. 1D).
CSC colony formation in response to CM was next assessed in
early breast cancer samples taken at the point of surgery for
primary tumour removal (Fig. 1b, n= 17, individual patients
denoted by BB6RC number. Green bars; ER positive samples,
Yellow bars; ER negative samples). CM significantly increased
mammosphere colony formation in 15/17 samples. This was seen
in both ER+ and ER− samples (mammosphere formation for
individual patients and representative mammosphere images
shown in Fig. 1b), and there was no significant difference between
oestrogen receptor subgroups when results from patients from
each subgroup were combined (Fig. 1c). Mammosphere self-
renewal (secondary mammosphere generation) was assessed in 4
of these samples (2 ER+, 2 ER−). Self-renewal was significantly
increased in cells which had been treated with CM compared to
control (p= 0.049) (Fig. 1d). These results indicate that normal
bone marrow-derived factors promote the colony forming ability
of breast CSCs. We also assessed the effect of CM on the ALDH+
cell population (a further CSC marker) using the Aldeflour
assay17 (Fig. 1e). CM treatment significant decreased the
percentage of ALDH+ cells in the MCF-7 cell line (p= 0.0139),
suggesting that bone marrow-secreted factors specifically enhance
the CSC functional property of colony formation. We next
assessed if the bone microenvironment was able to promote CSC
colony formation in vivo. MCF-7 cells were grown either in vitro,
or in vivo following subcutaneous or intra-femoral injection,
prior to tumour dissociation and assessment of mammo-
sphere colony formation. Cells which had grown in the femur
demonstrated a 4-fold increased mammosphere formation
capability ex vivo than cells grown in vitro or subcutaneously
(p= 0.0001). This effect diminished following in vitro passage
(p= 0.0012) (Fig. 1f). These results demonstrate that factors
produced by both human and mouse bone promote the ability of
breast CSCs to form colonies.
To further elucidate how bone marrow-derived factors drive
metastasis, we assessed if CM could additionally promote breast
cancer cell migration. When assessed by scratch assay, CM did
not induce migratory ability in MCF-7 cells (Fig. 1g). Therefore,
in our models, the bone microenvironment does not promote
migration of breast cancer cells, instead it specifically induces
breast CSCs to form colonies following arrival.
CSC colony formation in bone marrow is mediated by Wnt.
Next, we investigated signalling pathways promoting breast CSC
colony formation in bone. Wnt signalling was identified as a
strong candidate, due to both its well documented role in breast
CSC maintenance and tumour initiation (reviewed in ref. 18), and
its reported role in promoting metastatic colonisation in lung19.
We assessed if cancer cells grown in the bone microenvironment
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possessed increased Wnt signalling by assessing expression of the
Wnt target gene AXIN2. AXIN2 was increased fourfold in MCF-7
cells following CM treatment (p= 0.016), and 40 fold following
growth in the bone (p= 0.05) (Fig. 2a). We then assessed the
functional effect of adding recombinant Wnt3A to bone marrow
cultures. Recombinant Wnt3A recapitulated the effect of CM in
stimulating mammosphere colony formation in breast cancer cell
lines (MCF7; p < 0.0001, MDA-MB-231_BH; p < 0.0001)
(Fig. 2b), and inhibiting Wnt using recombinant human DKK1
(inhibitor of the Wnt co-receptor LRP520), or Vantictumab
(therapeutic antibody to Frizzled receptors21) (Western blots
showing reduction in protein levels of active β-catenin in Sup-
plementary Fig. 2A), reversed the effect of CM on breast CSC
colony formation in cell lines (MCF7; DKK1 p < 0.0001,
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Vantictumab p= 0.0432. MDA-MB-231_BH; DKK1 p < 0.0001,
Vantictumab p < 0.0001) (Supplementary Fig. 2B), and in early
breast cancer samples (DKK1; p= 0.0222, Vantictumab; p=
0.0060) (n= 10, Fig. 2c). Vantictumab also reversed the effect of
CM on breast CSC colony formation in a further ER+ cell line
(T47D, Supplementary Fig. 2C). Wnt inhibitors did not reduce
mammosphere formation in MCF-7 cells treated with control
media (Supplementary Fig. 2B). The specificity of this effect to
Wnt signalling was confirmed in MCF-7 cells by dual gene
knockdown of the LRP5 and LRP6 receptors using siRNA
(Supplementary Fig. 2D, E), and by using breast cancer cells
expressing a dominant negative TCF4 (EdTP from ref. 22)
(Supplementary Fig. 2F).
Next, the effect of anti-Wnt treatment on CSC colony
formation was tested in vivo. Mice were injected with MCF-7
cells intra-femorally and treated systemically with Vantictumab.
Mice were imaged 24 h post-injection to assess injection efficiency
(Untreated control; tumours cells present in 7/10 (70%) femurs,
Vantictumab; tumour cells present in 13/20 (65%) femurs)
(Supplementary Fig. 2G). Mice where tumour cells were not
observed 24 h post injection were excluded from further analysis.
Surprisingly, no significant difference in tumour formation was
observed between control and Vantictumab treated mice at
experiment termination (Control; tumours present in 5/7 (71%)
femurs, Vantictumab; tumours present in 11/13 (85%) femurs)
(Fig. 2d), and there was no difference in tumour growth
(Supplementary Fig. 2H). However, when breast cancer cells
were isolated from femurs and grown as mammospheres ex vivo
(representative image of mammosphere brightfield and tdTomato
expression in Fig. 2e), cells from Vantictumab treated mice
formed significantly less mammospheres than cells from control
mice (Fig. 2e). These data demonstrate that systemic inhibition of
Wnt signalling can reverse breast CSC colony formation induced
by the bone environment in vivo.
High Wnt signalling in tumours predicts poor prognosis.
Having identified Wnt signalling as a potential driver of bone
metastatic colonisation, we wanted to assess if expression of this
pathway in breast tumours had clinical significance. We assessed
gene expression levels of Wnt pathway components in published
Affymetrix datasets where metastasis data was known. We
compared patient outcome between patients with absent/mar-
ginal expression of the Wnt inhibitor DKK1 (i.e. patients with
high Wnt signalling tumours, 187 patients) to patients where
DKK1 was present (i.e. patients with low Wnt signalling tumours,
373 patients) in 560 primary tumours from 3 published Affy-
metrix datasets integrated with batch correction. When tumours
metastasised to bone (but not lung or brain), patients with higher
tumour expression of DKK1 had a better outcome than patients
whose tumours expressed lower levels of DKK1 (p= 0.01, log
rank test of a Cox-proportional hazards model) (Supplementary
Fig. 2I). In two further datasets, we restricted the analysis to
patients with only single-site bone metastases. In these patients,
the association between higher tumour expression of DKK1 and
better survival outcome was stronger (NKI; p= 0.005. Cb560;
p= 1e−5, log rank test of a Cox-proportional hazards model)
(Fig. 2f). This supports our pre-clinical data suggesting an asso-
ciation between Wnt signalling in tumours and the ability of
cancer cells to form colonies in bone.
To further explore the role of DKK1 specifically in colony
formation in the bone environment, we assessed if we could
induce a response to bone marrow CM by knocking down DKK1.
DKK1 was knocked down by siRNA in MDA-MB-231 cells
(Western blot in Supplementary Fig. 2J) which did not previously
respond to CM (as shown in Fig. 1a). When DKK1 was knocked
down, MDA-MB-231 cells became responsive to CM (p < 0.0001)
(Fig. 2g). We also compared DKK1 gene expression levels in the
MDA-MB-231 and MDA-MB-231_BH cell lines. The bone
homing MDA-MB-231_BH cells had significantly lower expres-
sion of DKK1 than the parental cells (p= 0.0031) (Fig, 2h). These
data add to our previous results indicating that Wnt signalling
promotes the ability of CSCs to form colonies in the bone
environment in vitro, and suggest a role for DKK1 specifically in
promoting this, which warrants further investigation in vivo.
Breast CSC colony formation is promoted by IL1β. Next, we
sought to identify the source of Wnt ligands driving breast CSC
colony formation. We assessed expression of Wnt ligands by
Affymetrix arrays in three bone marrow samples, comparing
bone marrow cultured for 3 weeks (where CM did not stimulate
breast CSC colony formation) to the same bone marrow cultured
for 8 weeks (where CM stimulated CSC colony formation) (CSC
colony formation shown in Supplementary Fig. 3A). Wnt ligand
expression did not increase in stimulatory bone marrow (Fig. 3a),
suggesting that the Wnt ligands promoting CSC colony formation
are not produced by the bone marrow. As confirmation, Wnt
ligand secretion from patient bone marrow was inhibited by
treating a bone marrow sample in culture with the porcupine
inhibitor (PORCNi) LGK97423 prior to collection of CM
(PORCNi inhibited Wnt signalling in a TCF4 driven Wnt
reporter assay in Wnt secreting L cells (Supplementary Fig. 3B)).
CM taken from bone marrow where Wnt ligand secretion had
been prevented did not affect the ability of CM to stimulate CSC
colony formation, confirming array results (p < 0.0001, PORCNi
on bone marrow (BM) in Fig. 3b). Next, we tested if Wnt ligands
are instead secreted by breast cancer cells, by treating MCF-7 cells
with PORCNi to prevent Wnt ligand secretion, prior to treatment
of these breast cancer cells with CM. PORCNi treated breast
cancer cells where Wnt ligand secretion was prevented no longer
responded to CM (PORCNi on MCF-7, Fig. 3b), indicating that
Wnt ligands driving Wnt signalling and CSC colony formation in
Fig. 1 Bone marrow-derived factors promote breast cancer stem cell colony formation. a Bone marrow conditioned media (CM) from three individual
patients increased mammosphere colony formation in 5/6 breast cancer cell lines (ER+; oestrogen receptor positive, ER−; oestrogen receptor negative)
compared to control treatment. Representative photomicrographs of mammospheres formed by MCF-7 and MDA-MB-231_BH cells treated with control
media (CONT) and CM are shown. Scale bar 100 µM. b CM increased mammosphere colony formation in 15/17 early breast cancer (EBC) samples. Error
bars represent six technical replicates for each sample. Representative photomicrographs of mammospheres formed by one sample treated with control
and CM are shown. Scale bar 100 µM. c Response to CM did not differ when samples were grouped by ER status (n= 9 ER+, 8 ER−). d CM increased
mammosphere self-renewal in four early breast cancer samples. e CM treatment did not increase the percentage of ALDH+ cells in the MCF-7 cell line.
Examples of representative FACS plots are shown. f Mammosphere formation of MCF-7 cells increased ex vivo when cells were grown intra-femorally,
compared to cells grown in vitro or subcutaneously in vivo, and this increase in mammosphere formation was lost following growth of isolated cells on
plastic (shown at passage 2, (P2)). g CM did not increase the ability of MCF-7 cells to migrate. Data is presented as percentage wound closure following
18 h in culture, adjusted for wound size. Representative images of cells at 0 and 18 h shown. Scale bar 200 µM. Dashed line shows wound edge at 18 h. All
graphs represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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breast cancer cells are produced by cancer cells in response to
intermediate bone marrow-derived factors.
To identify candidate bone marrow-derived factors driving
breast CSC colony formation, cytokine arrays were performed on
CM from a bone marrow sample at week 3 in culture (non-
stimulatory) and week 8 in culture (stimulatory) (Fig. 3c). Several
cytokines were increased in week 8 CM, with the largest fold
increases in IL15 and IL1β (Blots shown in Fig. 3c. Table showing
the 10 cytokines with the largest fold increases shown in
Supplementary Fig. 3C). Although IL15 and IL1β showed the
largest fold increases, overall levels of these cytokines were still
low, therefore the highest expressing cytokines (IL6 and IL8) were
also investigated. Inhibiting IL6, IL8 and IL15 in vitro using
neutralising antibodies in concurrent treatment with CM did not
prevent the stimulation of CSC colony formation in MCF-7 cells
by CM, however inhibition of IL1β by neutralising antibody
reversed this (Fig. 3d). As IL1β has previously been implicated in
bone metastasis11, this cytokine was viewed as a strong candidate
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for driving breast CSC colony formation in the bone. We
quantified IL1β expression in CM from four patients, comparing
IL1β levels between week 3 (non-stimulatory) CM and week 8–12
(stimulatory) CM. Confirming cytokine array results, IL1β levels
were low (range 4.95–8.76 pg/ml), but significantly increased in
stimulatory CM (p= 0.0025) (Fig. 3e). Immunohistochemical
analysis showed IL1β to be expressed by both mouse femur and
human rib bone (Fig. 3f), demonstrating that this cytokine is
present in the bone environment. This present study has utilised
immune deficient mice for in vivo experiments, however we also
assessed the presence of IL1β in immune competent models by
ELISA analysis and immunohistochemical staining of bone
sections. ELISA analysis showed significantly higher levels of
IL1β in the BALB/c immune competent model compared to the
NSG immune deficient model (p= 0.01), and this is supported by
immunohistochemical staining (Supplementary Fig. 3D, E).
Recombinant IL1β was added to CSC cultures in vitro, and it
recapitulated the effect of CM in stimulating CSC colony
formation in breast cancer cells (MCF7; p < 0.0001, MDA-MB-
231_BH; p < 0.0001) (Fig. 3g).
These results identify IL1β as a bone marrow-secreted factor,
however it has previously been suggested that tumour-derived
IL1β promotes bone metastasis11,12. To test this, we inhibited
IL1β by neutralising antibody in a bone marrow sample, prior to
treating breast cancer cells in culture with conditioned media
from this bone marrow and assessing CSC colony formation.
When IL1β was inhibited in bone marrow, CM from this bone
marrow no longer stimulated mammosphere formation in MCF-
7 cells (IL1β NA on bone marrow (BM), Fig. 3h). Next, we
inhibited IL1β by neutralising antibody in cancer cells, prior to
treatment with CM. IL1β inhibition in MCF-7 cells did not affect
the ability of CM to promote CSC colony formation (IL1βNA on
MCF-7, p < 0.0001, Fig. 3h). This indicates that the IL1β driving
Wnt-dependent colony formation in breast CSCs in vitro is bone
marrow derived.
IL1β signals through the IL1 receptor (IL1R). We therefore
sought to determine the location of this receptor in breast cancer
cells. We compared IL1R expression in MCF-7 cells between bulk
cells and anoikis resistant CSCs. ILR expression was increased in
CSCs (p= 0.05) (Fig. 3i). Therefore we hypothesise that
metastatic dissemination is selecting for IL1R+ CSCs that
colonise the IL1β-producing bone marrow.
Finally, we tested the effect of inhibiting IL1β signalling on
colony formation in the bone environment in vitro using
Anakinra, an IL1 receptor antagonist. Anakinra prevented
induction of CSC colony forming activity by CM in breast cancer
cell lines (MCF-7; p < 0.0001, MDA-MD-231_BH; p < 0.0001,
Supplementary Fig. 3F) and in patient derived samples (n= 3, p <
0.0001) (Fig. 3j). Anakinra did not reduce mammosphere
formation in cells treated with control media (Supplementary
Fig. 3F). This demonstrates that CSC colony formation driven by
IL1β from the bone environment can be prevented using a
clinically available drug.
IL1β promotes Wnt signalling via NFκB and CREB. Since bone
marrow-derived IL1β promotes breast CSC colony formation,
and this is Wnt dependent, we assessed the ability of IL1β to
activate the Wnt pathway. IL1β treatment significantly increased
Wnt signalling in a 293T cell Wnt-reporter model (p < 0.0001)
(Fig. 4a), and Lef1 Wnt target gene expression in breast cancer
cell lines (MCF7; p < 0.0001, MDA-MB-231_BH; p= 0.0083)
(Fig. 4b). To determine if specific Wnt ligands are produced by
breast cancer cells in response to IL1β, and to assess if any dif-
ferences were seen between breast cancer subtypes, Wnt ligand
gene expression was assessed in ER+ MCF-7 cells, ER− MDA-
MB-231_BH cells, and patient derived samples (n= 3 ER+, n= 3
ER−) following IL1β treatment. In MCF-7 cells expression of
Wnt3A, Wnt4, Wnt5A, Wnt7A and Wnt10A were significantly
increased upon IL1β treatment (Wnt3A; p= 0.015, Wnt4; p=
0.0028, Wnt5A; p= 0.0194, Wnt7A; p= 0.0056, Wnt10A; p=
0.0373) (Fig. 4c), and in MDA-MB-231_BH cells expression of
Wnt 3A and 7A were significantly increased upon IL1β treatment
(Wnt3A; p= 0.0449, Wnt 7A; p= 0.0139) (Fig. 4c). In patient
derived samples, increases in expression of Wnt ligands >1.5 fold
were observed in both ER+ and ER− samples, with the specific
Wnt ligands induced varying between samples (Fig. 4d) (3 ER+
and 3 ER− samples included, samples were either primary breast
cancers (ER+ 1 and ER− 1) or metastatic cells derived from
ascitic fluids (ER+ 2,3 and ER− 2,3)). Interestingly, both ER+
cell lines and patient samples appear to show a higher degree of
induction of Wnt ligand expression than ER−. These data
demonstrate that Wnt ligands are produced in breast cancer cell
lines and patient samples in response to IL1β, and the Wnt
ligands driving CSC metastatic colony formation may vary
between patients.
To determine the intra-cellular signalling mechanism by which
IL1β promotes Wnt signalling, dual-luciferase pathway reporter
arrays were performed on MCF-7 cells following IL1β treatment.
Luciferase reporting for the NFKB and CREB pathways were
increased in MCF-7 cells (Fig. 4e), and an increase in
phosphorylation of CREB and nuclear NFKB following IL1β
treatment was confirmed in both MCF7 and MDA-MB-231_BH
cells (Fig. 4f, g). When NFKB signalling was inhibited using
Sulfasalazine24, or CREB signalling was inhibited using KG-50125,
there was a significant reduction in IL1β-induced Wnt reporting
in 293T cells (Fig. 4h), and a significant reduction in IL1β-
induced expression of Lef1 in both MCF-7 (Sulfasalazine; p=
0.0003, KG-501; p= 0.0084) and MDA-MB-231_BH cells
(Sulfasalazine; p= 0.0045, KG-501 p= 0.0007) (Fig. 4i). Treat-
ment with Sulfasalazine significantly reduced IL1β-induced
Fig. 2 CSC colony formation in bone marrow is mediated by Wnt signalling. a Treatment of MCF-7 cells with CM in vitro, or intra-femoral growth in vivo
increased expression of AXIN2 compared to cells treated with control media in vitro. b Addition of 100 nM recombinant Wnt (rWnt) to control media
replicated the effect of CM in increasing mammosphere formation in MCF-7 and MDA-MB-231_BH cells. Adding Wnt to CM did not further increase
mammosphere formation (bars labelled as CM+Wnt). c Inhibition of Wnt signalling with 50 ng/ml DKK1 or 50 µg/ml Vantictumab reversed induction of
mammosphere formation by CM in early breast cancer samples in vitro (n= 10). d There was no significant difference in tumour formation between
control and Vantictumab treated mice following intra-femoral injection of MCF-7 cells. e Cells isolated from femurs of Vantictumab treated mice formed
significantly fewer mammsopheres ex vivo than cells isolated from control mice. Representative photomicrographs shows brightfield and tdTomato images
of mammospheres. Scale bar 150 µM. f Survival analysis based on DKK1 expression (Low (orange) vs High (purple)) in 2 published datasets (NKI, Cb560)
in patients with bone metastases. Low DKK1 expression in primary breast cancers was associated with poor outcomes in patients with bone metastasis.
(NKI; significant cut points P < 0.05 92/244 (38%), Cb560; significant cut points P < 0.05 170/420 (40%)). HR; Hazard ratio. BMFS; Bone metastasis free
survival. g Knockdown of DKK1 with 25 nM siRNA sensitised MDA-MB-231 cells to CM, resulting in induction of mammosphere formation. h DKK1 gene
expression is decreased in MDA-MB-231_BH cells compared to the parental MDA-MB-231 cells. Data presented as fold change in gene expression in
MDA-MB-231_BH cells compared to parental cells. All graphs represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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expression of Wnt3A (p= 0.0045), Wnt4 (p= 0.0003) and
Wnt7A (p < 0.0001), and treatment with KG-501 significantly
reduced IL1β-induced expression of Wnt3A (p= 0.0022), Wnt4
(p= 0.0141), Wnt5A (p < 0.0001) and Wnt7A (p < 0.0001) in
MCF-7 cells (Fig. 4j). These findings establish CREB and NKFB
as important cellular pathways downstream of IL1β and upstream
of Wnt secretion and signalling. We also tested the effect of
inhibiting NFKB and CREB signalling on CSC colony formation
in vitro. Inhibiting NFKB and CREB reversed the effect of CM in
cell lines (MCF7; sulfasalazine p < 0.0001, KG-501 p < 0.0001.
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MDA-MB-231_BH; sulfasalazine p < 0.0001, KG-501 p < 0.0001)
(Supplementary Fig. 4) and patient derived samples (n= 3,
sulfasalazine; p= 0.0004, KG-501; p < 0.0001) (Fig. 4k). In cell
lines, combined treatment with both sulfasalazine and KG501
further reduced mammosphere formation compared to either
treatment alone (MCF7; CM+ sulfasalazine vs CM+ Sulfasala-
zine+KG501 p < 0.0001, CM+ KG501 vs CM+ Sulfasalazine+
KG501 p= 0.0020. MDA-MB-231_BH; CM+ sulfasalazine vs
CM+ Sulfasalazine+KG501 p < 0.0001, CM+ KG501 vs CM+
Sulfasalazine+KG501 p < 0.0001) (Supplementary Fig. 4) .Taken
together, our data demonstrate that IL1β stimulates Wnt-
dependent CSC colony formation in the bone environment via
an induction of NFκB and CREB signalling in breast cancer cells.
Inhibition of IL1β-Wnt signalling prevents bone metastasis.
Finally, we assessed if inhibiting microenvironmental IL1β or
tumour cell Wnt signalling could prevent bone metastases in vivo.
We initially used MDA-MB-231_BH cells as these are bone
homing following tail vein injection16. All mice were injected with
tumour cells, and mice were treated with an anti-mouse IL1β
antibody, the anti-human Frizzled receptor antibody Vantictu-
mab, or with vehicle control. Tumour formation was monitored
by bioluminescence, and assessed and quantified by histological
examination of bone tissue sections from all hind limbs. We also
assessed the effect of IL1β and Wnt inhibition on the bone
environment by micro-CT. Metastatic breast cancer patients
often experience bone loss as part of their disease progression,
therefore any treatments which promote bone volume could be
advantageous for these patients.
IL1β inhibition reduced tumour formation from 11/16 hind
limbs in control mice to 3/16 hind limbs in treated mice (69% vs.
19%, p= 0.0113, chi squared test) (Representative luciferase
images of whole mice shown in Supplementary Fig. 5A, excised
limbs in Supplementary Fig. 5B, representative H&E stained
sections in Fig. 5a). Anti-IL1β treatment also significantly
increased trabecular bone volume compared to control mice
(representative images and graphical representation of 8 scored
femurs per treatment group in Fig. 5b). Systemic Wnt inhibition
reduced tumour formation from 9/16 hind limbs of control mice
to 1/14 hind limbs in treated mice (56% vs 7%, p= 0.0067, chi
squared test) (Representative luciferase images of whole mice
shown in Supplementary Fig. 5C, LightTools images of excised
hind limbs in Supplementary Fig. 5D, representative H&E stained
sections in Fig. 5c). Wnt inhibition appeared to increase
trabecular bone volume compared to untreated tumour-bearing
mice (%BV/TV p= 0.0034, graphical representation in Supple-
mentary Fig. 5E), however this was due to a reduction in total
bone volume (representative bone images in Fig. 5d, arrows
denote areas of bone loss; analysis of cortical bone volume in
Supplementary Fig. 5F showing reduction in cortical bone volume
in Vantictumab treated mice (p < 0.0001)) rather than a bone
building effect.
Our in vitro data suggests that Wnt inhibition does not prevent
tumour migration, but instead prevents colony formation in the
bone. To confirm this in vivo, two-photon analysis of injected
DiD labelled tumour cells was performed to assess if tumour cells
were present in the bone of mice treated with Vantictumab,
despite less overt tumours developing in this group. Twenty-eight
days following injection, similar numbers of tumour cells were
present in the proximal tibiae of control or Vantictumab treated
mice (Fig. 5e), demonstrating that inhibiting Wnt signalling does
not prevent tumour cells homing to bone.
Given that IL1β inhibition prevented tumour colonisation in
bone whilst promoting trabecular bone volume, we also assessed
the ability of IL1β inhibition to prevent metastatic colonisation in
a spontaneously bone metastatic ER+ PR+Her2− patient
derived xenograft (PDX) model (BB3RC32 from ref. 26) following
intra-cardiac injection. IL1β was inhibited through systemic
treatment with Anakinra, and tumour formation assessed as
previously. IL1β inhibition reduced tumour formation from 10/24
hind limb tumours in control mice to 3/22 hind limb tumours in
Anakinra treated mice (42% vs 14%, p= 0.021, chi squared test)
(Representative images of excised hind limbs in Supplementary
Fig. 5G, representative H&E images in Fig. 5f). As we had
previously observed in our cell line model that tumour cells were
present in the bones of treated mice which did not develop overt
metastases, we also assessed this in this model. Tumour cells were
present in Anakinra treated mice which had not developed
metastases at experiment termination (Supplementary Fig. 5H),
suggesting that, as in the cell line model, inhibiting this signalling
pathway prevents colonisation of disseminated tumour cells in
bone, rather than tumour cell homing to bone. Taken together,
these PDX data demonstrate that in this more clinically relevant
model, systemic inhibition of IL1β using a clinically available
drug prevents metastatic colonisation. Our in vivo data strongly
support in vitro results, and demonstrate that targeting IL1β-Wnt
signalling can prevent disseminated CSCs from forming overt
bone metastases. The signalling mechanism identified in this
study, and drugs tested which could be utilised to inhibit it
clinically, are shown in Fig. 5g.
Discussion
In this work we establish IL1β-NFKB/CREB-Wnt as a novel
signalling pathway regulating the metastatic colonisation of dis-
seminated breast CSCs in the bone microenvironment.
Fig. 3 Wnt-dependent breast CSC colony formation is promoted by IL1β. a Gene expression levels of Wnt ligands did not increase from week 3 to week 8
bone marrow taken from three patients (patient numbers: 140, 147, 148). Data is presented as log2 fold change in gene expression from week 3 to week 8. b
Treating bone marrow in culture with 100 µM porcupine inhibitor (PORCNi) LGK974 for 72 h prior to taking CM did not prevent CM stimulating
mammosphere formation in MCF-7 cells (PORCNi on BM). Treating MCF-7 cells with 100 µM of LGK974 for 72 h prior to the addition of CM prevented
stimulation in mammosphere formation (PORCNi on MCF7). c IL15 and IL1β showed the largest increase from week 3 to week 8 CM when analysed by
cytokine array (n= 1). d Inhibition of IL6, IL8 or IL15 with 5 µg/ml neutralising antibody did not prevent induction of mammosphere formation by CM in
MCF-7 cells, whereas inhibition of IL1β with 5 µg/ml neutralising antibody prevented CM from increasing mammosphere formation. e IL1β levels were
significantly increased in week 8–12 stimulatory CM compared to week 3 non-stimulatory CM (n= 4). f IL1β is expressed by both normal mouse and human
bone. Staining is representative of three sections from three independent samples. Femur taken from 8 week old NSG mice. Negative controls (no primary
antibody) are shown. Scale bar 100 µM. g The addition of 10 ng/ml recombinant IL1β to control media replicated the effect of CM in stimulating
mammosphere formation in MCF-7 and MDA-MB-231_BH. h Treating a bone marrow sample in culture with 5 µg/ml of IL1β neutralising antibody for 72 h
prior to collection of CM prevented stimulation of mammosphere formation in MCF-7 cells (IL1βNA on BM). Treating MCF-7 cells with 5 µg/ml of IL1β
neutralising antibody for 72 h prior to the addition of CM did not prevent stimulation in mammosphere formation by CM (IL1βNA on MCF7). i IL1R gene
expression is increased in the anoikis resistant (AR) cancer stem cell population in MCF-7 cells. j 10 µg/ml Anakinra reversed the induction in
mammosphere formation by CM in early breast cancer samples (n= 3). All graphs represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Using primary tissue, we have shown for the first time that
normal human bone marrow-derived factors enhance the ability
of breast CSCs to form metastatic colonies. Interestingly,
although we saw an increase in breast CSC colony formation in
response to the bone environment, this was not accompanied by
an increase in ALDH+ cell number. It has previously been
reported that there are multiple CSC populations within tumours
with different functional properties27, and our data support this.
Of particular clinical interest is the finding that there is no dif-
ference in CSC colony forming response to bone marrow-derived
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factors between ER+ and ER− samples, despite the majority of
breast cancers which metastasise to the bone being ER+28. Based
on this finding, we speculate that the clinical difference between
subtypes could be due to a difference in pre-metastatic niche
formation by ER+ samples, differential homing ability, or a dif-
ference in Wnt ligand expression in response to IL1β.
We have identified IL1β as a key cytokine produced by human
bone marrow which enhances the ability of breast CSCs to form
colonies. IL1β has long been proposed as an important cytokine
for metastasis, both in breast and other cancers9–12. A metastasis
promoting role for IL1β is not totally clear however, and con-
tradictory recent data has also suggested that IL1β prevents cell
proliferation29. Our study adds further weight for a promoting
role of IL1β in metastasis, and challenges the assumption that
IL1β is tumour derived. Having established a role for micro-
environmental IL1β in promoting metastasis, next it will be
important to determine specific cells within the bone micro-
environment producing this cytokine. Previous studies have
shown that multiple cell types within the bone marrow produce
IL1β, including both immune cells and non-immune cells30–32.
Mechanistically, we demonstrate that bone marrow-derived
IL1β promotes metastatic colony formation through activation of
intracellular NFKB/CREB signalling and Wnt ligand production
by cancer cells. Wnt signalling has been shown to promote
metastatic colonisation in the lung19, but this role downstream of
IL1β in bone is novel. Interestingly, a recent study suggests that
tumour-derived Wnt promotes IL1β secretion by macrophages,
suggesting the possibility of a feed-forward signalling mechanism
promoting metastasis33. Elucidation of this signalling pathway
has identified multiple drug targets for clinical use. Canakinumab
and Anakinra that inhibit IL1β signalling, and the NFKB inhi-
bitor Sulfasalazine, are in clinical usage for other indications24,34–
36. Vantictumab is in phase 1b clinical trials in patients with
advanced cancer, and the porcupine inhibitor LGK974 is being
tested in Phase I clinical trials37. It has been reported that Van-
tictumab has adverse effects on patient bone in clinical trials13,
however a clinical strategy of reduced dosing and co-
administration of zoledronic acid mitigates adverse events18,
rendering this drug suitable for patient use. In our intra-femoral
model, anti-Wnt treatment did not alter tumour take in bone or
tumour growth, despite demonstrating an effect of CSC colony
forming activity ex vivo. Vantictumab has previously been shown
to inhibit tumour growth following subcutaneous injection21, and
we predict the lack of effect seen in our study may either have
been due to the large number of cells injected (and a lack of
selection for CSCs), or the nature of the model, where tumour
cells are injected directly into the bone.
It should be noted that there are limitations to the models we
have used within this study. It has been shown that tumour
promoting pre-metastatic niches are established at distant sites
before the arrival of disseminated cells38,39, and since our model
uses bone marrow from non-cancer patients, it fails to address
this. In vivo, no single model has been identified which accurately
recapitulates the multiple steps of human breast cancer metastasis,
and we have selected models to allow us to best study the final
colonisation step. A further limitation of our models is the use of
immune-compromised mice. Whilst these are essential to study
metastasis of human tumour cells in vivo, they do not give us any
insight into the interplay between IL1β-Wnt inhibition and the
immune system during metastatic colonisation. However, a
recently published paper has shown that inhibiting IL1β in mouse
models enhances tumour cell immunity by synergising with anti-
PD-140, which is very promising for future combination therapies.
A question this study does not answer is why only some
patients experience colonisation of disseminated tumour cells in
bone. Thirty percent of breast cancer patients have DTCs in the
bone marrow at the time of diagnosis4, yet many of these will
never develop overt metastases. Based on our data, we hypothe-
sise that this could be due to either particular properties of the
primary tumour, or a change in the bone microenvironment in
individual patients. We have preliminary data showing that
tumour cell-conditioned medium induces IL1β production by the
bone marrow (Supplementary Fig. 6). This indicates one
mechanism by which an increase in bone marrow IL1β has the
potential to promote metastatic colonisation in breast cancer
patients, but is a point for further investigation.
In summary, we have identified IL1β-NFKB/CREB-Wnt sig-
nalling as a novel pathway promoting the colonisation of breast
CSCs in the bone microenvironment, and we have demonstrated
that drugs targeting this pathway prevent both bone metastases
in vivo and colony formation by breast CSCs in vitro. This work
therefore provides a strong rationale for consideration of inhi-
bitors of this pathway as an adjuvant therapeutic strategy in
breast cancer to prevent metastatic tumour cell colonisation in
bone, subject to confirmation of our results in immune competent
mouse models.
Methods
Compliance with ethical standards. All patients underwent fully informed con-
sent in accordance with local ethics committee guidelines. Ethical approval for
metastatic samples was granted by the Central Office for Research Ethics Com-
mittee study number #05/Q1403/159. Early breast cancer samples were collected
via the MCRC Biobank which is licensed by the Human Tissue Authority (licence
number: 30004) and approved as a research tissue bank by the South Manchester
Research Ethics Committee (Ref: 07/H1003/161+ 5). All in vivo experiments were
performed in accordance with the UK Home Office Animals (Scientific Proce-
dures) Act 1986. The ethical compliance and study protocol were approved by the
CRUK Manchester Institute Animal Welfare and Ethical Research Board
(AWERB) and the UK Home Office. In vivo experiments utilising MDA-MB-
231_BH cells and intra-cardiac injection of PDX cells were carried out at the
University of Sheffield with Home Office approval under licence 70/8964. In vivo
experiments utilising intra-femoral and subcutaneous injections of MCF-7 cells
Fig. 4 IL1β promotes Wnt signalling in breast cancer cells via an induction in NFKB and CREB. a IL1β treatment stimulated Wnt reporting in a 293T 7TCF
cell line. 100 nM Wnt3A treatment included as a positive control. b IL1β treatment increased expression of Lef1 in both MCF-7 and MDA-MB-231_BH cells
compared to treatment with control media. c IL1β treatment increased gene expression levels of Wnt ligands Wnt3A, 4, 5A, 7A and 10A in MCF-7 cells and
Wnt3A and 7A in MDA-MB-231_BH cells. d IL1β treatment increased gene expression levels of some Wnt ligands in patient derived samples (n= 6). ER
positive samples; green bars, ER negative samples; orange bars. Dashed line set as fold change of 1. Note split axis to show lower fold changes. e IL1β
treatment increased NFKB and CRE signalling in MCF-7 cells. f IL1β treatment increased phospho CREB protein, but not total CREB protein in MCF-7 and
MDA-MB-231_BH cells. Actin was used as a loading control. g IL1β treatment increased nuclear phospho NFKB p65 protein in MCF-7 and MDA-MB-
231_BH cells. Lamin was used as a nuclear loading control. h Treatment with sulfasalazine or KG-501 reversed the induction of Wnt signalling by IL1β in a
293T 7TCF reporting assay. i Treatment with sulfasalazine or KG-501 reversed the induction of Lef1 gene expression by IL1β treatment in both MCF-7 and
MDA-MB-231_BH cells. j Treatment with sulfasalazine or KG-501 reversed the induction in gene expression of some Wnt ligands by IL1β . k Sulfasalazine
or KG501 treatment reversed the induction in mammosphere formation by CM in early breast cancer patient derived samples (n= 3). Data presented as
fold change in percentage mammosphere formation normalised to cells treated with control media. All graphs represent mean ± SEM, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001
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and were carried out at the University of Manchester with Home Office approval
under licence 40/3645.
Cell lines. Cell lines were purchased from ATTC (MCF-7 (catalogue number
ATCC® HTB-22), T47D (ATCC® HTB-133), 293T (ATCC® CRL-1573), MDA-
MB-231 (ATCC® HTB-26). Wnt secreting L cells were a kind gift from Professor
Keith Brennan, University of Manchester. hFOB1.19 cells were a kind gift from Dr
Suzanne Johnson, University of Manchester. SUM149 and SUM159 cells were a
kind gift from Professor Göran Landberg, University of Manchester. All cell lines
were authenticated by multiplex PCR assay (Life Technologies, Paisley, UK) and
verified as mycoplasma free on a monthly basis. MCF-7, T47D, 293T, SUM149,
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SUM159 and Wnt secreting L cells were grown adherently in DMEM complete
medium (DMEM/10% foetal bovine serum/2mM L-glutamine). MDA-MB-231 and
MDA-MB-231_BH cells (bone homing variants of MDA-MB-231, originally
named MDA-MB-231_IV when derived in ref. 16) were grown adherently in RPMI
complete media (RPMI/10% foetal bovine serum/2mM L-glutamine). hFOB1.19
cells were grown in DMEMF12 (10% FBS, 0.3 mg/ml G418). Cells were grown to
passage 30 before discarding.
Bone marrow culture. Bone marrow samples were extracted from patients
undergoing radical nephrectomy for non- malignant renal failure. Bone marrow
samples were cultured at a density of 2 × 106 ml−1 in long-term culture medium
(Iscove's Modified Dulbecco's Medium at 350 mOsm containing 10% FCS, 10%
horse serum and 50 μM hydrocortisone—referred to as control media or CONT in
experiments) on plastic at 33 °C in 5% CO2 in air for 20 weeks without passage.
Fifty percent of bone marrow culture media was removed and replenished weekly
to sustain bone marrow growth41. This conditioned media (referred to as bone
marrow conditioned media or CM) was used in experiments. For donor char-
acteristics see Supplementary Table 1.
Breast cancer patient samples. Early breast cancer samples were collected from
patients undergoing primary tumour removal at three NHS trusts in Greater
Manchester, UK. Early breast cancers were disaggregated and digested in 4.7 ml
RPMI plus enzymes from the Miltenyi tumour dissociation kit (130-095-929) as
per manufacturer’s instructions for 2 h. Cells were strained through a 70 µM filter
(BD, 352340) followed by a 40 µM filter (BD, 352340) and centrifuged at 1000 × g
for 5 min at room temperature to pellet cells26 prior to mammosphere culture.
Clinico-pathological details are presented in Supplementary Table 2. Metastatic
samples were collected from palliative pleural or ascitic drainage procedures at The
Christie NHS Foundation Trust. Metastatic samples were first centrifuged at
1000 × g for 10 min to pellet cells. Pellets were resuspended in PBS and blood cells
were removed by centrifugation of the cell suspension through 0.5 volumes of
Lymphoprep solution (Axis Shield, Dundee, UK) at 800 × g for 20 min26, prior to
mammosphere culture. Clinico-pathological details are listed in Supplementary
Table 3. 19/24 patient samples used were treatment naïve at the time of surgery.
Where patient derived samples cells were grown in culture this was overnight in
DMEM F12 Glutamax supplemented with 10% FBS, 10 µg/ml insulin, 10 µg/ml
hydrocortisone and 5 µg/ml EGF.
PDX samples. PDX models were created by implanting breast cancer samples into
female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice in accordance with the
UK Home Office Animals (Scientific Procedures) Act 1986. Early breast cancers
were implanted as 2 × 2 mm3 fragments, and metastatic samples were injected as
1 × 106 cancer cells. Oestrogen supplementation in drinking water was provided for
mice with ER positive tumours at a concentration of 8 μg/ml. Tumour growth was
measured twice weekly using callipers. When tumours reached 1.3 cm3 mice were
culled and tissue fragments were digested as for early breast cancer patient samples
above26. Where cells derived from PDX tumours were grown in culture this was
overnight in DMEM F12 Glutamax supplemented with 10% FBS, 10 µg/ml insulin,
10 µg/ml hydrocortisone and 5 µg/ml EGF.
Cell treatments. Cell lines and patient derived samples were treated with the
following prior to downstream assays: 50 ng/ml DKK1 (GF170, Milipore), 50 µg/ml
Vantictumab (Oncomed), 100 nm Wnt3A (5036-WN, R&D systems), 100 µM
LGK974 (S7143, Selleckchem), 10 ng/ml rIL15 (247-ILB, R&D systems), 10 ng/ml
rIL1β (201-LB, R&D systems), 5 µg/ml IL1β neutralising antibody (MAB201, R&D
systems), 5 µg/ml IL15 neutralising antibody (MAB-274, R&D systems), 5 µg/ml
IL6 neutralising antibody (MAB2061, R&D systems), 5 µg/ml IL8 neutralising
antibody (MAB208, R&D systems), 10 µg/ml Anakinra (Amgen, Cambridge, UK),
5 mM Sulfasalazine (Sigma), 10uM KG-501 (Sigma). Treatment times for indivi-
dual assays are detailed below.
Mammosphere assay. For mammosphere culture, a single cell suspension was
prepared by manual disaggregation of cells through a 25 gauge needle, and a total
of 500 cells/cm2 were plated in appropriate polyHEMA (Poly (2-hydro-
xyethylmethacrylate)) coated tissue culture plates in mammosphere medium
(DMEM-F12/B27/20 ng/ml EGF/Pen-Strep)15. To assess the effect of bone marrow
conditioned media on mammosphere formation, cell lines were treated in mono-
layer with conditioned media or control media (+/− inhibitors) for 72 h prior to
plating in mammosphere culture. Patient samples cells were plated directly into a
50:50 ratio of mammosphere media and bone marrow conditioned media or
control media (+/− inhibitors). Cells were cultured for five days (cell lines) or
seven days (primary samples) before mammospheres greater than 50 μm were
counted. Mammosphere-forming efficiency (MFE) was calculated by dividing the
number of mammospheres formed by the number of cells plated and expressed as a
percentage. Mammosphere data is presented as percentage mammosphere for-
mation in treated samples, normalised to percentage mammosphere formation in
control samples. For all cell line experiments, each experiment represents six
technical replicates and three biological repeats. For patient sample experiments,
each experiment was carried out with as many technical replicates as possible given
the number of cells extracted from the sample (a minimum of three, and up to six
technical replicates) and the number of biological repeats (the number of patients
tested) is included in each figure. Mammosphere self-renewal was assessed when
the number of mammospheres grown in primary culture was sufficient for onward
passage. To assess self-renewal, mammospheres were counted, centrifuged (115 ×
g), and dissociated into a single cell suspension by incubation for 2 min at 37 °C in
trypsin EDTA 0.125% (Sigma), followed by mechanical dissociation through a 25
gauge needle15. No additional treatments were added in secondary generation.
Mammosphere self-renewal was calculated by dividing the number of secondary
mammospheres formed by the number of primary mammospheres formed.
Aldefluor assay. The Aldefluor assay (Stemcell Technologies) was performed
according to manufacturer’s instructions. 7-aminoactinomycin D (7AAD, BD) was
used to exclude dead cells. Data were acquired on a LSR II (BD) flow cytometer and
analysed using the BD FACSDiva™ software.
Scratch assay. MCF-7 cells were plated on tissue culture plates to create a con-
fluent monolayer. A straight line was scraped with a p200 pipette tip and debris
removed by washing cells once with growth media. Cells were incubated for 18 h in
either control media or CM, and images taken under a brightfield microscope.
RNA and real-time PCR. RNA was prepared from human bone marrow samples
using the Qiagen RNEasy Micro kit, and from breast cancer cells using the Qiagen
RNEasy Mini kit, as per manufacturer’s instructions. RNA concentration and
purity was determined using an ND-1000 spectrophotometer (NanoDrop Tech-
nologies). For RT-PCR 1 µg of RNA was reversed transcribed using the TaqMan
Reverse Transcription Reagents (Applied Biosystems, N8080234) as per manu-
facturer’s instructions. Quantitative real-time PCR reactions were performed on a
QS3 PCR machine (Applied Biosystems) using TaqMan® Universal PCR Master
Mix (Applied Biosystems) and Taqman predesigned gene expression assays (LEF1:
hs01547250_m1, 18S: hs99999901-s1, AXIN2: hs00610344_m1, GAPDH:
hs03929097_g1, ACTB: hs99999903_m1) (Thermo Fisher). CT values were nor-
malised to the average CT value of housekeeping genes (β-actin, GAPDH, 18S) and
expression levels were calculated using the ΔΔCt method. For Wnt PCR arrays
RNA was extracted using the Qiagen RNEasy Mini kit. RNA was reversed
Fig. 5 Systemic inhibition of either IL1β or Wnt signalling prevents bone metastasis in vivo. a Anti-mouse IL1β treatment reduced hind limb bone metastases
in a spontaneous MDA-MB-231_BH mouse model. Histology shows tumour cells in bones of control mice (M1, M2) vs. tumour free hind limbs in treated
mice (M9, M16). Tumour areas are marked as T. Scale bar 500 µM. Statistical significance assessed by chi squared test, tumour vs. no tumour in treated
vs. untreated mice. b Anti-IL1β treatment increased trabecular bone volume at experiment termination. Example images presented from a control mouse
(M3) and a mouse treated with IL1β antibody (M11). Data presented as percentage bone volume/total volume (%BV/TV) (n= 8). c Vantictumab
treatment reduced spontaneous hind limb bone metastases in the MDA-MB-231_BH model. Histology shows tumour cells in bones of control mice (M15,
M19) vs. tumour free hind limbs in treated mice (M1, M2). Tumour areas are marked as T. Scale bar 500 µM. Statistical significance assessed by chi
squared test, tumour vs. no tumour in treated vs. untreated mice. d Vantictumab treated mice showed a thinning of cortical and spongy bone.
Representative images of control mice (M11, M15) and Vantictumab treated mice (M5, M7) are presented. Arrows denote areas of bone loss. e No
significant difference in the number of DiD labelled tumour cells in control and Vantictumab treated mice was seen 30 days following injection of tumour
cells (n= 4 control, n= 5 Vantictumab treated). f Anakinra reduced hind limb tumours in an ER+ PDX (BB3RC32) model following intra-cardiac injection
of tumour cells. Histology shows tumour cells in bones of control mice (M23, M28) vs. tumour free hind limbs in treated mice (M12, M15). Tumour areas
are marked as T. Scale bar 500 µM. Statistical significance was assessed by chi squared test, tumour vs. no tumour in treated vs. untreated mice.
g Our proposed model of signalling pathways underpinning bone colonisation by metastatic breast cancer cells. All graphs represent mean ± SEM, *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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transcribed using the Qiagen RT2 First Strand kit as per manufacturer’s instruc-
tions, followed by the Human WNT signalling pathway PCR array as per manu-
facturer’s instructions. CT values were normalised to the average CT value of
housekeeping genes (β-actin, B2M, GAPDH, HPRT1 and RPLPO) and expression
levels were calculated using the ΔΔCt method.
Microarray analysis. Total RNA was quality assessed by Agilent Bioanalyzer.
cDNA was hybridised to Human U133 2.0 Plus GeneChips (Affymetrix, High
Wycombe, UK) according to the GeneChip® Expression Analysis Technical
Manual (Affymetrix, Rev. 5). Probe set mapping was performed using RMA
(Robust Multichip Average) Express42. Arrays were background corrected and
Quantile normalised before the data was Probe Level Model summarised. Chip
pseudo-images were then assessed for QC purposes before assessment of RLE
(relative log expression) median values. RMA expression values were produced and
expressed in the log2 scale. Expression levels were then compared using log2 fold
changes and visualised by colour plot.
Lentiviruses generation. The following lentiviral plasmids were used: 7xTcf-
FFluc//SV40 (as detailed in ref. 22), pFULT (bicistronic tdTomato and luciferase
expressing vector43), EdTP22. Lentivirus was prepared using the Lenti-Pac FIV
expression Packaging Kit (GeneCopea) as per manufacturer’s instructions.
293T cells were infected with lentivirus in transfection medium (DMEM/5% Heat
Inactivated foetal bovine serum/L-glutamine) with 8 µg/ml polybrene. Media was
changed to general culture medium (DMEM/10% foetal bovine serum/L-gluta-
mine) 24 h post infection and infected cells were selected with 5 µg/ml puromycin
from 48 h post infection.
Wnt transcriptional assay. 293T 7xTcf-FFluc//SV40 infected cells were treated
with 100 nm recombinant Wnt3A or 10 ng/ml rIL1β+/− 5 mM Sulfasalazine or
10uM KG-501) for 24 h in serum free media prior to lysis with 1× Passive lysis
buffer (5×, Promega, E 1941), rocked for 15 min and luminescence assessed using
the Dual-Glo Luciferase assay system (Promega, E2920) following manufacturer’s
instructions. Luciferase activity was measured using a luminometer (Promega,
Glomax Multi+ Detection System with Instinct Software).
siRNA knockdown of LRP5, LRP6 and DKK1. ON-TARGET Plus siRNA to LRP5,
LRP6 and DKK1 (Dharmacon) was used to transfect cells using Dharmafect
(Dharmacon) according to manufacturer’s instructions in serum free media. All
siRNA were used at a concentration of 25 nM. Media was changed after 24 h, and
cells were incubated for either 48 h (DKK1) or 72 h (LRP5, LRP6) prior to use.
Western blotting. A total of 40 µg was utilised for each sample. Primary anti-
bodies for Western blotting were: LRP5 (1:1000, Cell signalling 3889), LRP6
(1:1000, Abcam ab75358), Non-phospho active β-catenin (1:1000, Cell signalling
8814), DKK1 (1:100, Cell Signalling 4687), NFKB p65 (1:1000 8242P, Cell Sig-
nalling), phospho-CREB Ser133 (1:1000, 9198S). Membranes were incubated with
primary antibody at 4 0C overnight with gentle shaking. Immunoreactive proteins
were detected by enhanced chemiluminescence (Pierce). Uncropped versions of
key blots are included in the Source Data files.
Cytokine experiments. Cytokines present in CM were assessed using RayBio
Human Cytokine Array 5 (R&D systems) according to manufacturer’s instructions.
MacBiophotonics Image J (1.42l) was used to quantitate cytokine spots as per
manufacturer’s instructions. Raw densitometry data was extracted by identifying a
single exposure with a high signal to noise ratio, measuring the density of each spot
using circles of equal size dimensions, and determining the summed signal density
across the entire circle for each spot. Background signal was then subtracted and
data was normalised based on positive control signals for each array.
ELISA. IL1β was detected in human bone marrow conditioned media using the
Human IL1β ELISA MAX™ Deluxe ELISA kit (Biolegend 437004) and in mouse
bone marrow samples using the Mouse 1β ELISA MAX™ Deluxe ELISA kit (Bio-
legend 432601) according to manufacturer‘s instructions. Absorbance at 450 nm
was read using a plate reader (Varioskan LUX multimode reader, ThermoFisher
Scientific) and Gen5 Data Analysis software.
Immunohistochemistry. Immunohistochemistry was performed on a Leica Bond
using standard protocol F with increased primary antibody incubation time and
without antigen retrieval. Antibodies used were: IL1β (1:500, abcam ab9722).
Signalling arrays. Assessment of signalling pathways in breast cancer cells fol-
lowing IL1β treatment was performed using Cignal 45 Pathway Reporter Arrays
(Qiagen) as per manufacturer’s instructions. Cells were either treated as control
(media only) or with 10 ng/ml IL1β for 16 h. The luciferase assay was then carried
out using Dual-Glo Luciferase assay system as per manufacturer’s instructions.
Data were analysed using the provided Data Analysis Template (Qiagen).
In vivo experiments. For subcutaneous experiments, 1x106 MCF-7 cells were
injected into each flank of 12 week old female NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ, Charles River) mice. Mice were Supplemented with 0.18 mg
oestrogen pellets (Innovative Research America) and euthanised when tumours
reached a total tumour volume of 1.3 cm3. Tumours were digested using the
Miltenyi tumour dissociation kit (130-095-929) as per manufacturer’s instructions.
For intra-femoral injections, 5 × 105 dual tdTomato and luciferase (pFULT, kindly
provided by Dr Gambhir, Stanford University, CA43), expressing MCF-7 cells in
10 μl PBS were injected directly into the femurs of 8 week old female NOD/SCID
mice using a Atraucan® single shot needle (B Braun Medical Ltd) (5 control
(untreated) mice, 10 treated mice, both femurs injected). Mice were not supple-
mented with oestrogen. Mice were either treated with Vantictumab (15 mg kg−1
weekly by intra-peritoneal injection) or control IP (sterile PBS) from 3 days prior to
cell injections and for the duration of the experiment. Bioluminescence imaging
was carried out using a Bruker In-Vivo Xtreme imaging system. All mice were
culled between 6 and 8 weeks following cell injection. Femurs were collected in
RPMI on ice, and washed in 70% ethanol followed by three washes in sterile PBS.
Cells were flushed from femurs into cold RPMI using a 25 G needle. Bone ends
were crushed with a scalpel and passed through a 100uM filter into RPMI. Cells
were pelleted at 500 G for 7 min, and cells were counted based on tdTomato
expression before plating as mammospheres. For spontaneous bone metastases
experiments, tumour cells were pre-labelled with 25uM DiD (1,1′-dioctadecyl-′, 3′-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate.Life Technologies, UK)
for 15 min44. 5 × 105 GFP and luciferase labelled MDA-MB-231_BH cells were
injected intravenously via the tail vein into 8 week old female BALB/c Nude mice
(n= 10/group) (this cell line is bone seeking following tail vein injection16). Mice
were monitored for a period of 30 days following cell injection and all culled on
Day 31. Mice were treated with either an antibody to cleaved IL1β (1400.24.17,
Invitrogen, UK; 2 mg kg−1 subcutaneously three times weekly) or sterile PBS, or
Vantictumab (15 mg kg−1 intra-peritoneal injection weekly) or sterile PBS. Injec-
tions started prior to tumour injection (day −1 anti-IL1β antibody, day −3
Vantictumab) and continued throughout the experiment. Mice were imaged for
tumour development by GFP/luciferase weekly using an IVIS imaging system, and
hind limbs were extracted for individual ex vivo imaging on termination of the
experiment. Right hind limbs were flash frozen in liquid N2 for two-photon ana-
lysis of tumour cells within bone. Left hind limbs were fixed in 4% PFA for
microcomputed tomography (μCT) analysis before decalcification in 1%PFA/0.5%
EDTA and processing for histology. The presence of tumours in hind limbs was
determined by visual examination of H&E stained slides by two independent sci-
entists. μCT analysis assessed trabecular bone volume (BV) as a percentage of total
tissue volume (TV) (BV/TV).
For the PDX experiment, BB3RC32 cells (ER+, PR+, Her2− PDX as described
in26) were labelled with luciferase by electroporation and 1 × 105 cells injected into
the left cardiac ventricle of 6 week female NSG mice (12 mice/group). Cells were
not selected for luciferase expression prior to injection, due to the risk of damage to
PDX cells. Mice were treated with Anakinra (1 mg kg−1 subcutaneously) or sterile
PBS daily until mice became moribund (58 days post tumour injection). Mice were
monitored for tumour development and tumours were detected using methods
detailed above. DiD cell two-photon analysis could not be carried out in PDX cells,
due to these cells not taking up the DiD label, therefore the presence of
disseminated tumour cells in bone was assessed by two-photon imaging of
phycoerythrin-conjugated cytokeratin 19 (sc376126, Santa Cruz Biotechnology).
Two-photon microscopy. Tibiae were imaged using a multiphoton confocal
microscope (LSM510 upright; Zeiss, Cambridge, UK). DiD labelled cells were
visualised using a 633-nm visible laser, bone was detected using a 900-nm multi-
photon Chameleon laser (Coherent, Santa Clara, CA). Images were reconstructed
in LSM software version 4.2 (Zeiss) and numbers of cells per mm3 were counted
using Volocity 3D Image Analysis software 6.01 (PerkinElmer, Cambridge, UK).
DKK1 survival analysis. Three publicly available Affymetrix datasets (MSK82
[GSE2603]45, EMC192 [GSE12276]46, EMC286 [GSE2034]47) of primary breast
tumours with information on the site of metastasis were integrated following RMA
normalisation and the Combat48 batch correction approach and duplicates
removed. Similarly gene expression data for 2999 primary breast tumours from 17
published Affymetrix studies were integrated as described previously49. MAS5
detection calls50 were used to define in which samples DKK1 was called ‘present’.
Associations with outcome were assessed by Kaplan Meier analysis using the
Survival R package51.
Statistical methods. Data are represented as mean ± SEM taken over a minimum
of three independent experiments with three technical replicates per experiment,
unless otherwise stated. For mammosphere experiments each independent
experiment contained six technical replicates, and all replicates were included in
statistical analyses. Unless stated otherwise, statistical significance was measured
using parametric testing, assuming equal variance, with standard unpaired t-tests
used to assess difference between test and control samples. Differences were con-
sidered statistically significant if the two-tailed probability value (p) was ≤0.05. All
graphs represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data and metadata on PDX models are available in PDX Finder (pdxfinder.org) and in
the EurOPDX data portal (http://dataportal.europdx.eu). All other data that support the
findings of this study are available from the corresponding authors upon reasonable
request.
Received: 26 February 2019; Accepted: 2 October 2019;
References
1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated
Cancer Incidence, Mortality and Prevalence Worldwide in 2012, http://
globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (2012).
2. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer
Cell 13, 58–68 (2008).
3. Hosseini, H. et al. Early dissemination seeds metastasis in breast cancer.
Nature, https://doi.org/10.1038/nature20785 (2016).
4. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast
cancer. New Engl. J. Med. 353, 793–802 (2005).
5. Ghajar, C. M. Metastasis prevention by targeting the dormant niche. Nat. Rev.
Cancer 15, 238–247 (2015).
6. Early Breast Cancer Trialists' Collaborative, G. Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
7. Lawson, D. A. et al. Single-cell analysis reveals a stem-cell program in human
metastatic breast cancer cells. Nature 526, 131–135 (2015).
8. Balic, M. et al. Most early disseminated cancer cells detected in bone marrow
of breast cancer patients have a putative breast cancer stem cell phenotype.
Clin. Cancer Res. 12, 5615–5621 (2006).
9. Bani, M. R., Garofalo, A., Scanziani, E. & Giavazzi, R. Effect of interleukin-1-
beta on metastasis formation in different tumor systems. J. Natl. Cancer Inst.
83, 119–123 (1991).
10. Coffelt, S. B. et al. IL-17-producing gammadelta T cells and neutrophils
conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).
11. Holen, I. et al. IL-1 drives breast cancer growth and bone metastasis in vivo.
Oncotarget, https://doi.org/10.18632/oncotarget.12289 (2016).
12. Tulotta, C. et al. Endogenous production of IL-1B by breast cancer cells drives
metastasis and colonisation of the bone microenvironment. Clin. Cancer Res.
https://doi.org/10.1158/1078–0432.CCR-18–2202 (2019).
13. Ridker, P. M. et al. Effect of interleukin-1beta inhibition with canakinumab on
incident lung cancer in patients with atherosclerosis: exploratory results from
a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842
(2017).
14. Dontu, G. et al. In vitro propagation and transcriptional profiling of human
mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 (2003).
15. Shaw, F. L. et al. A detailed mammosphere assay protocol for the
quantification of breast stem cell activity. J. Mammary Gland Biol. Neoplasia
17, 111–117 (2012).
16. Nutter, F. et al. Different molecular profiles are associated with breast cancer
cell homing compared with colonisation of bone: evidence using a novel bone-
seeking cell line. Endocr.-Relat. Cancer 21, 327–341 (2014).
17. Charafe-Jauffret, E. et al. Breast cancer cell lines contain functional cancer
stem cells with metastatic capacity and a distinct molecular signature. Cancer
Res. 69, 1302–1313 (2009).
18. de Sousa, E. M. F. & Vermeulen, L. Wnt Signaling in Cancer Stem Cell
Biology. Cancers 8, https://doi.org/10.3390/cancers8070060 (2016).
19. Malanchi, I. et al. Interactions between cancer stem cells and their niche
govern metastatic colonization. Nature 481, 85–89 (2012).
20. He, X., Semenov, M., Tamai, K. & Zeng, X. LDL receptor-related proteins 5
and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131,
1663–1677 (2004).
21. Gurney, A. et al. Wnt pathway inhibition via the targeting of Frizzled
receptors results in decreased growth and tumorigenicity of human tumors.
Proc. Natl Acad. Sci. USA 109, 11717–11722 (2012).
22. Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt
signaling pathway. PLoS ONE 5, e9370 (2010).
23. Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine
by LGK974. Proc. Natl Acad. Sci. USA 110, 20224–20229 (2013).
24. Wahl, C., Liptay, S., Adler, G. & Schmid, R. M. Sulfasalazine: a potent and
specific inhibitor of nuclear factor kappa B. J. Clin. Investig. 101, 1163–1174
(1998).
25. Best, J. L. et al. Identification of small-molecule antagonists that inhibit an
activator: coactivator interaction. Proc. Natl Acad. Sci. USA 101, 17622–17627
(2004).
26. Eyre, R. et al. Patient-derived Mammosphere and Xenograft Tumour
Initiation Correlates with Progression to Metastasis. J. Mammary Gland Biol.
Neoplasia, https://doi.org/10.1007/s10911–016–9361–8 (2016).
27. Liu, S. et al. Breast cancer stem cells transition between epithelial and
mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2,
78–91 (2014).
28. Savci-Heijink, C. D. et al. Retrospective analysis of metastatic behaviour of
breast cancer subtypes. Breast Cancer Res. Treat. 150, 547–557 (2015).
29. Castano, Z. et al. IL-1beta inflammatory response driven by primary breast
cancer prevents metastasis-initiating cell colonization. Nat. Cell Biol. 20,
1084–1097 (2018).
30. de Mooij, C. E. M., Netea, M. G., van der Velden, W. & Blijlevens, N. M. A.
Targeting the interleukin-1 pathway in patients with hematological disorders.
Blood 129, 3155–3164 (2017).
31. Carey, A. et al. Identification of Interleukin-1 by Functional Screening as a
Key Mediator of Cellular Expansion and Disease Progression in Acute
Myeloid Leukemia. Cell Rep. 18, 3204–3218 (2017).
32. Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in
homeostasis and leukemia. Cell 177, 1915–1932 e1916 (2019).
33. Wellenstein, M. D. et al. Loss of p53 triggers WNT-dependent systemic
inflammation to drive breast cancer metastasis. Nature 572, 538–542 (2019).
34. Mertens, M. & Singh, J. A. Anakinra for rheumatoid arthritis: a systematic
review. J. Rheumatol. 36, 1118–1125 (2009).
35. Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile
idiopathic arthritis. New Engl. J. Med. 367, 2396–2406 (2012).
36. Ruperto, N. et al. A phase II, multicenter, open-label study evaluating dosing
and preliminary safety and efficacy of canakinumab in systemic juvenile
idiopathic arthritis with active systemic features. Arthritis Rheumatism 64,
557–567 (2012).
37. ClinicalTrials.gov. A Study of LGK974 in Patients With Malignancies
Dependent on Wnt Ligands, <https://clinicaltrials.gov/ct2/show/
NCT01351103> (2016).
38. Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone
marrow cell recruitment to form the premetastatic niche. Cancer Cell 15,
35–44 (2009).
39. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells
toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891
(2012).
40. Kaplanov, I. et al. Blocking IL-1beta reverses the immunosuppression in
mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.
Proc. Natl Acad. Sci. USA 116, 1361–1369 (2019).
41. Coutinho, L. H., Gilleece, M. H., de Wynter, E., Will, A. & Testa, N. G. in
Haemopoiesis: A Practical Approach (eds Testa, N. G. & Molineux, G.) 75–100
(Oxford University Press, 1993).
42. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data.
Nucleic Acids Res. 31, e15 (2003).
43. Liu, H. et al. Cancer stem cells from human breast tumors are involved in
spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci.
USA 107, 18115–18120 (2010).
44. Ottewell, P. D. et al. Zoledronic acid has differential antitumor activity in the
pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res.
20, 2922–2932 (2014).
45. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature
436, 518–524 (2005).
46. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain.
Nature 459, 1005–1009 (2009).
47. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet 365, 671–679 (2005).
48. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 8, 118–127
(2007).
49. Moleirinho, S. et al. KIBRA exhibits MST-independent functional
regulation of the Hippo signaling pathway in mammals. Oncogene 32,
1821–1830 (2013).
50. Rajagopalan, D. A comparison of statistical methods for analysis of
high density oligonucleotide array data. Bioinformatics 19, 1469–1476
(2003).
51. Therneau, T. A Package for Survival Analysis in S. version 2.38, https://CRAN.
R-project.org/package=survival. (2005).
Acknowledgements
This study was funded by Breast Cancer Now (Grant numbers: 2016MayPR734, MAN-
Q1and MAN-Q2), NIHR Manchester Biomedical Research Centre (IS-BRC-1215-
20007), EdiREX Horizon 2020 grant No.731105, MRC-MR/P000096/1 (PDO and CT)
and Weston Park Hospital (PDO and DL). We would like to thank all patients who
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12807-0
14 NATURE COMMUNICATIONS |         (2019) 10:5016 | https://doi.org/10.1038/s41467-019-12807-0 | www.nature.com/naturecommunications
donated tissue to this study, and the Manchester Cancer Research Centre Biobank for
consenting patients and collecting tissue. We would like to thank Simon Mendez-Ferrer
and Ya-Hsuan Ho (Wellcome - MRC Cambridge Stem Cell Institute, University of
Cambridge) for helpful discussions.
Author contributions
R.C., R.E., S.H., G.F. conceived the project; R.C., R.E., P.O., G.F., M.B., A.S., J.M. con-
ceived and designed the analysis; R.E., D.A., A.S.G., K.S., J.M., C.H., B.S., D.L., C.T., J.S.
collected the data; A.G., N.C., S.H. contributed data or analysis tools; R.E., D.A., A.S.G.,
K.S., J.M., D.L., C.T., P.O. performed the analysis; R.E., S.H., A.S., P.O., G.F., R.C. wrote
the paper.
Competing interests
A.G. is Chief Scientific Officer at Oncomed Pharmaceuticals. All other authors declare no
competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
019-12807-0.
Correspondence and requests for materials should be addressed to P.D.O. or R.B.C.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12807-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5016 | https://doi.org/10.1038/s41467-019-12807-0 | www.nature.com/naturecommunications 15
